# Contineum Therapeutics, Inc.: financial statements, quarterly

CTNM · Nasdaq · CIK 1855175 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctnm.md) · [Financials](/companies/ctnm/financials.md) · [Filings](/companies/ctnm/filings.md) · [Insiders](/companies/ctnm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctnm/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001437749-25-006458.md) | not reported | [0.0](/filings/0001437749-24-026680.md) | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001437749-25-006458.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [6.5](/filings/0001437749-24-033616.md) | [8.0 d](/filings/0001437749-25-006458.md) | [7.8](/filings/0001437749-25-016835.md) | [7.9](/filings/0001437749-25-024852.md) | [9.7](/filings/0001437749-25-032427.md) | [13.0 d](/filings/0001628280-26-015165.md) | [13.7](/filings/0001628280-26-030614.md) | [14.1](/filings/0001628280-26-051054.md) | [11.0](/filings/0001437749-25-032427.md) | [12.8 d](/filings/0001628280-26-015165.md) | [11.6](/filings/0001628280-26-030614.md) | [12.7](/filings/0001628280-26-051054.md) |
| Operating income | $m | [(8.1)](/filings/0001437749-24-033616.md) | [(9.7) d](/filings/0001437749-25-006458.md) | [(9.9)](/filings/0001437749-25-016835.md) | [(10.9)](/filings/0001437749-25-024852.md) | [(13.0)](/filings/0001437749-25-032427.md) | [(17.0) d](/filings/0001628280-26-015165.md) | [(18.1)](/filings/0001628280-26-030614.md) | [(17.9)](/filings/0001628280-26-051054.md) | [(14.9)](/filings/0001437749-25-032427.md) | [(17.1) d](/filings/0001628280-26-015165.md) | [(16.9)](/filings/0001628280-26-030614.md) | [(17.4)](/filings/0001628280-26-051054.md) |
| Interest expense | $m | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001437749-25-006458.md) | [0.0](/filings/0001437749-24-017320.md) | [0.0](/filings/0001437749-24-026680.md) | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001437749-25-006458.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0001437749-24-033616.md) | [(0.2) d](/filings/0001437749-25-006458.md) | [0.0](/filings/0001437749-24-017320.md) | [0.0](/filings/0001437749-24-026680.md) | [0.0](/filings/0001437749-24-033616.md) | [0.0 d](/filings/0001628280-26-015165.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(6.3)](/filings/0001437749-24-033616.md) | [(7.8) d](/filings/0001437749-25-006458.md) | [(8.4)](/filings/0001437749-25-032427.md) | [(9.0)](/filings/0001437749-25-032427.md) | [(10.3)](/filings/0001437749-25-032427.md) | [(14.6) d](/filings/0001628280-26-015165.md) | [(16.0)](/filings/0001628280-26-051054.md) | [(16.0)](/filings/0001628280-26-051054.md) | [(12.8)](/filings/0001437749-25-032427.md) | [(15.2) d](/filings/0001628280-26-015165.md) | [(14.5)](/filings/0001628280-26-051054.md) | [(15.2)](/filings/0001628280-26-051054.md) |
| Diluted EPS | $ per share | [(2.69)](/filings/0001437749-24-033616.md) | not reported | not reported | [(0.39)](/filings/0001437749-24-026680.md) | [(0.40)](/filings/0001437749-24-033616.md) | not reported | [(0.62)](/filings/0001628280-26-030614.md) | [(0.62)](/filings/0001628280-26-051054.md) | not reported | not reported | [(0.39)](/filings/0001628280-26-030614.md) | [(0.40)](/filings/0001628280-26-051054.md) |
| Basic EPS | $ per share | [(2.69)](/filings/0001437749-24-033616.md) | not reported | [(3.55)](/filings/0001437749-25-016835.md) | [(0.39)](/filings/0001437749-25-024852.md) | [(0.40)](/filings/0001437749-25-032427.md) | not reported | [(0.62)](/filings/0001628280-26-030614.md) | [(0.62)](/filings/0001628280-26-051054.md) | [(0.45)](/filings/0001437749-25-032427.md) | not reported | [(0.39)](/filings/0001628280-26-030614.md) | [(0.40)](/filings/0001628280-26-051054.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [15.5](/filings/0001437749-25-006458.md) | [16.3](/filings/0001437749-24-017320.md) | [77.2](/filings/0001437749-24-026680.md) | [40.9](/filings/0001437749-24-033616.md) | [21.9](/filings/0001628280-26-015165.md) | [22.5](/filings/0001437749-25-016835.md) | [20.8](/filings/0001437749-25-024852.md) | [42.6](/filings/0001437749-25-032427.md) | [75.6](/filings/0001628280-26-051054.md) | [20.2](/filings/0001628280-26-030614.md) | [14.7](/filings/0001628280-26-051054.md) |
| Current assets | $m | not reported | [128](/filings/0001437749-25-006458.md) | [120](/filings/0001437749-24-017320.md) | [220](/filings/0001437749-24-026680.md) | [215](/filings/0001437749-24-033616.md) | [206](/filings/0001628280-26-015165.md) | [192](/filings/0001437749-25-016835.md) | [177](/filings/0001437749-25-024852.md) | [185](/filings/0001437749-25-032427.md) | [268](/filings/0001628280-26-051054.md) | [253](/filings/0001628280-26-030614.md) | [243](/filings/0001628280-26-051054.md) |
| Total assets | $m | not reported | [130](/filings/0001437749-25-006458.md) | [124](/filings/0001437749-24-017320.md) | [221](/filings/0001437749-24-026680.md) | [216](/filings/0001437749-24-033616.md) | [213](/filings/0001628280-26-015165.md) | [198](/filings/0001437749-25-016835.md) | [183](/filings/0001437749-25-024852.md) | [191](/filings/0001437749-25-032427.md) | [277](/filings/0001628280-26-051054.md) | [261](/filings/0001628280-26-030614.md) | [250](/filings/0001628280-26-051054.md) |
| Current liabilities | $m | not reported | [5.5](/filings/0001437749-25-006458.md) | [6.2](/filings/0001437749-24-017320.md) | [3.7](/filings/0001437749-24-026680.md) | [5.8](/filings/0001437749-24-033616.md) | [10.0](/filings/0001628280-26-015165.md) | [8.9](/filings/0001437749-25-016835.md) | [7.2](/filings/0001437749-25-024852.md) | [6.4](/filings/0001437749-25-032427.md) | [9.7](/filings/0001628280-26-051054.md) | [6.7](/filings/0001628280-26-030614.md) | [6.5](/filings/0001628280-26-051054.md) |
| Total liabilities | $m | not reported | [5.7](/filings/0001437749-25-006458.md) | [6.6](/filings/0001437749-24-017320.md) | [3.9](/filings/0001437749-24-026680.md) | [5.8](/filings/0001437749-24-033616.md) | [14.8](/filings/0001628280-26-015165.md) | [13.5](/filings/0001437749-25-016835.md) | [11.5](/filings/0001437749-25-024852.md) | [10.4](/filings/0001437749-25-032427.md) | [15.7](/filings/0001628280-26-051054.md) | [11.3](/filings/0001628280-26-030614.md) | [10.7](/filings/0001628280-26-051054.md) |
| Shareholders' equity | $m | [(61.1)](/filings/0001437749-24-033616.md) | [(67.9)](/filings/0001628280-26-015165.md) | [(75.6)](/filings/0001437749-25-032427.md) | [218](/filings/0001437749-25-032427.md) | [210](/filings/0001437749-25-032427.md) | [198](/filings/0001628280-26-051054.md) | [185](/filings/0001628280-26-051054.md) | [171](/filings/0001628280-26-051054.md) | [180](/filings/0001437749-25-032427.md) | [261](/filings/0001628280-26-051054.md) | [250](/filings/0001628280-26-051054.md) | [240](/filings/0001628280-26-051054.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.4) d](/filings/0001437749-24-033616.md) | [(10.7) d](/filings/0001437749-25-006458.md) | [(8.0)](/filings/0001437749-25-016835.md) | [(8.5) d](/filings/0001437749-25-024852.md) | [(6.2) d](/filings/0001437749-25-032427.md) | [(10.2) d](/filings/0001628280-26-015165.md) | [(14.4)](/filings/0001628280-26-030614.md) | [(15.7) d](/filings/0001628280-26-051054.md) | [(12.2) d](/filings/0001437749-25-032427.md) | [(13.0) d](/filings/0001628280-26-015165.md) | [(16.3)](/filings/0001628280-26-030614.md) | [(11.5) d](/filings/0001628280-26-051054.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001437749-24-033616.md) | [0.3 d](/filings/0001437749-25-006458.md) | [0.1](/filings/0001437749-25-016835.md) | [0.1 d](/filings/0001437749-25-024852.md) | [0.1 d](/filings/0001437749-25-032427.md) | [0.2 d](/filings/0001628280-26-015165.md) | [0.0](/filings/0001628280-26-030614.md) | [0.0 d](/filings/0001628280-26-051054.md) | [0.1 d](/filings/0001437749-25-032427.md) | [0.0 d](/filings/0001628280-26-015165.md) | [0.3](/filings/0001628280-26-030614.md) | [0.0 d](/filings/0001628280-26-051054.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.3](/filings/0001437749-24-017320.md) | [3.5](/filings/0001437749-24-026680.md) | [2.3](/filings/0001437749-24-033616.md) | [2.4](/filings/0001437749-24-017320.md) | [23.4](/filings/0001437749-24-026680.md) | [25.7](/filings/0001437749-24-033616.md) | [25.9](/filings/0001628280-26-030614.md) | [25.9](/filings/0001628280-26-051054.md) | [37.3](/filings/0001628280-26-030614.md) | [37.5](/filings/0001628280-26-051054.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 23,099,173 at 2025-10-27, from the cover of the [10-Q filed 2025-10-30](/filings/0001437749-25-032427.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.